Cytokinetics vs Krystal Biotech
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Cytokinetics and Krystal Biotech side by side, using each oneβs latest annual report. Here is what stands out:
- Krystal Biotech is the larger business, with $389M of revenue in fiscal 2025 against $88.0M for Cytokinetics, about 4.4 times as much.
- Cytokinetics grew revenue faster (376.6%, against 33.9%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against β695.4%).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against β607.5%).
Who comes out ahead
Of the 4 measures where higher (or lower) is clearly better, how many each company leads.
Cytokinetics
CYTK
1/4
Revenue growth
Krystal Biotech
KRYS
3/4
Operating marginNet marginFCF margin
Side by side
Best in the row
| Latest fiscal year | CYTK FY25 | KRYS FY25 |
|---|---|---|
| Size | ||
| Market cap | β | $9.6B |
| Revenue | $88.0M | $389M |
| Free cash flow | β$535M | $189M |
| Net income | β$785M | $205M |
| Growth | ||
| Revenue growth | 376.6% | 33.9% |
| 5-year growth | 9.5% | β |
| Share count change | β | 0.7% |
| Profitability | ||
| Gross margin | β | β |
| Operating margin | β695.4% | 41.5% |
| Net margin | β891.6% | 52.6% |
| FCF margin | β607.5% | 48.6% |
| Return on capital | β | 43.6% |
| Return on equity | β | 18.9% |
| Balance sheet | ||
| Net debt | β$912M | β$828M |
| Net debt / EBITDA | β | β5.0x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | β | 39.0x |
| Piotroski F-score | β | 5 |
Ten years
Revenue
FY16
CYTK $106M
KRYS β
FY17
CYTK $13.4M
KRYS β
FY18
CYTK $31.5M
KRYS β
FY19
CYTK $26.9M
KRYS β
FY20
CYTK $55.8M
KRYS β
FY21
CYTK $70.4M
KRYS $0.0M
FY22
CYTK $94.6M
KRYS $0.0M
FY23
CYTK $7.5M
KRYS $50.7M
FY24
CYTK $18.5M
KRYS $291M
FY25
CYTK $88.0M
KRYS $389M
CYTK
KRYS
Operating margin
FY16
CYTK 17.6%
KRYS β
FY17
CYTK β848.3%
KRYS β
FY18
CYTK β282.3%
KRYS β
FY19
CYTK β368.0%
KRYS β
FY20
CYTK β168.3%
KRYS β
FY21
CYTK β264.5%
KRYS β
FY22
CYTK β342.8%
KRYS β
FY23
CYTK β6,589.7%
KRYS β216.2%
FY24
CYTK β2,902.7%
KRYS 22.6%
FY25
CYTK β695.4%
KRYS 41.5%
CYTK
KRYS
Free cash flow
FY16
CYTK $35.4M
KRYS β$1.3M
FY17
CYTK β$105M
KRYS β$4.1M
FY18
CYTK β$102M
KRYS β$11.7M
FY19
CYTK β$93.5M
KRYS β$25.1M
FY20
CYTK β$2.1M
KRYS β$40.9M
FY21
CYTK β$191M
KRYS β$116M
FY22
CYTK β$311M
KRYS β$154M
FY23
CYTK β$416M
KRYS β$101M
FY24
CYTK β$400M
KRYS $119M
FY25
CYTK β$535M
KRYS $189M
CYTK
KRYS
Return on capital
FY16
CYTK β
KRYS β
FY17
CYTK β
KRYS β
FY18
CYTK β
KRYS β
FY19
CYTK β
KRYS β
FY20
CYTK β
KRYS β
FY21
CYTK β
KRYS β61.2%
FY22
CYTK β
KRYS β76.9%
FY23
CYTK β
KRYS β47.7%
FY24
CYTK β
KRYS 20.7%
FY25
CYTK β
KRYS 43.6%
CYTK
KRYS
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.